Raven Biotechnologies Overview
- Founded
-
1999
- Status
-
Acquired/Merged
- Latest Deal Type
-
M&A
- Latest Deal Amount
-
$25M
Raven Biotechnologies General Information
Description
Developer of monoclonal antibody therapeutics created to treat cancer. The company's lead product candidate, RAV12, targets adenocarcinomas and simultaneously identifies cell-surface drug targets and the antibody therapeutics to regulate them, identifying novel target antigens and therapeutic candidates in their native configuration in the intact cell membrane for the treatment of gastrointestinal and other cancers.
Contact Information
Primary Office
- 1140 Veterans Boulevard
- South San Francisco, CA 94080
- United States
Raven Biotechnologies Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 10. Merger/Acquisition | 17-Jul-2008 | $25M | 00000 | 0000 | Completed | Generating Revenue/Not Profitable |
| 9. Merger/Acquisition | 01-Mar-2008 | Cancelled | Clinical Trials - General | |||
| 8. Convertible Debt | 12-Nov-2007 | 00.00 | 00000 | Completed | Generating Revenue/Not Profitable | |
| 7. Later Stage VC (Series D) | 12-Oct-2005 | 000.00 | 00000 | Completed | Clinical Trials - General | |
| 6. Later Stage VC | 28-Oct-2004 | 00000 | 00000 | Completed | Generating Revenue | |
| 5. Later Stage VC (Series C) | 13-Mar-2003 | 000.00 | 00000 | Completed | Pre-Clinical Trials | |
| 4. Later Stage VC (Series C) | 02-Jan-2003 | 000.00 | 000.00 | Completed | Pre-Clinical Trials | |
| 3. Early Stage VC (Series B) | 08-Jan-2001 | 000.00 | 000.00 | Completed | Pre-Clinical Trials | |
| 2. Early Stage VC (Series A) | Completed | Pre-Clinical Trials | ||||
| 1. Accelerator/Incubator | 01-Jan-2000 | Completed | Pre-Clinical Trials |
Raven Biotechnologies Patents
Raven Biotechnologies Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| US-20080206819-A1 | Growing cells in a perfusion system using induction agents without a substantial loss of cell viability; agent is sodium butyrate | Inactive | 21-Aug-2006 | 0000000000 | |
| US-20080124329-A1 | Using combinations of antitumor agents and chimeric immunoglobulins as tool in treatment and prevention of infectious, cell proliferative, autoimmune, nervous system, cardiovascular and inflamatory disorders | Inactive | 05-Jul-2006 | 000000000 | |
| US-20100028344-A1 | Conditioned cell immunization | Inactive | 05-Jul-2006 | 000000000 | |
| CA-2597198-A1 | Antibodies that bind to epha2 and methods of use thereof | Active | 04-Feb-2005 | 000000000 | |
| EP-1846450-A2 | Antibodies that bind to epha2 and methods of use thereof | Active | 04-Feb-2005 | C07K16/30 |
Raven Biotechnologies Former Investors (15)
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds | Contact Info |
|---|---|---|---|---|---|
| Bear Stearns Health InnoVentures Management | Venture Capital | Minority | 000 0000 | 000000 0 | |
| CIDC Consultants | Venture Capital | Minority | 000 0000 | 000000 0 | |
| Cercano Management | Venture Capital | Minority | 000 0000 | 000000 0 | |
| China Investment & Development | Venture Capital | Minority | 000 0000 | 000000 0 | |
| Cogene Ventures | Venture Capital | Minority | 000 0000 | 000000 0 |